Gemcitabine

Catalog No.S1714 Synonyms: LY-188011, NSC 613327

Gemcitabine  Chemical Structure

Molecular Weight(MW): 263.2

Gemcitabine is a very potent and specific deoxycytidine analogue, used as chemotherapy.

Size Price Stock Quantity  
In DMSO USD 130 In stock
USD 97 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • Mice were administered either vehicle, gemcitabine (120 mg/kg [PaCa2]) or 20 mg/kg of BBI608 i.p. After killing, tumors were collected after 7 or 14 d of treatment, for Paca-2 and FaDu cells, respectively. Single-cell suspensions were obtained after animal killing and sterile removal of tumors. Live cells were then counted and used to measure their ability to form spheres when cultured in cancer stem cell media.

    Proc Natl Acad Sci USA, 2015, 112(6): 1839-44. Gemcitabine purchased from Selleck.

    RNA incorporating drugs induce SG assembly. HeLa cells were treated with the RNA incorporating agents 5-azacytidine (50 uM) and 6-thioguanine (10 uM), or the DNA incorporating agents trifluorothymidine (10 uM) and gemcitabine (100 nM) for 72 h. Subsequently, the cellular localization of the SG marker protein TIAR (green) and the P-body marker protein DCP1 (red) was analyzed. Nuclei were stained with Hoechst. Scale bars represent 20 um.

    Nucleic Acids Res 2014 42(10), 6436-47. Gemcitabine purchased from Selleck.

  • Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Gemcitabine for 48h. Cell survival was measured by a standarad MTT assay.

    Dr. Helen Sadik of Johns Hopkins University. Gemcitabine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Gemcitabine is a very potent and specific deoxycytidine analogue, used as chemotherapy.
In vitro

Gemcitabine results in 50% inhibition of growth in the CCRF-CEM human leukemia cell culture assay with IC50 of 1 ng/ml. Gemcitabine combined with deoxycytidine provides about a 1000-fold decrease in biological activity. [1] Gemcitabine combined with C225 results in additive cytotoxic effects that increased with increasing gemcitabine concentrations in human pancreatic carcinoma L3.6pl cells. [2] Gemcitabine combined with Cisplatin results in synergistic effect in wild-type A2780 and cisplatin-resistant ADDP cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 NHPibodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTBwMECwOFU5KG6P MonvV2FPT0WU
ES4 NYm4XpJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDoTWM2OD1yLkCwNFY2OyCwTR?= NF;acIxUSU6JRWK=
ACHN MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PSfWlEPTB;MD6wNFA5QDdibl2= NFu2TVdUSU6JRWK=
KYSE-510 MlXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljYTWM2OD1yLkCwNFk4PSCwTR?= NFfzcXRUSU6JRWK=
EW-7 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nITGlEPTB;MD6wNFI2QCCwTR?= MoDTV2FPT0WU
BFTC-905 MofNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nTeGlEPTB;MD6wNFUyPSCwTR?= Mm\rV2FPT0WU
KE-37 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\XO2lEPTB;MD6wNFU3OSCwTR?= MojzV2FPT0WU
SBC-5 M2r6cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUniTphSUUN3ME2wMlAxPTdibl2= NWC3RZRKW0GQR1XS
NKM-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTBwMEC3NFkhdk1? MVXTRW5ITVJ?
RH-1 NW\me2h2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlj3TWM2OD1yLkCwO|E5KG6P MYrTRW5ITVJ?
ALL-PO M{T3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTBwMEC4N{BvVQ>? MUjTRW5ITVJ?
QIMR-WIL NI\IZnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\iPZdKSzVyPUCuNFA5QTRibl2= MkPSV2FPT0WU
A375 M1jHd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPUTWM2OD1yLkCwPVk2KG6P NEfHNHBUSU6JRWK=
SIG-M5 NE\Jd2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\H[mRRUUN3ME2wMlAyODRibl2= NYjQXmwyW0GQR1XS
KGN NIW1[2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXkWlZ6UUN3ME2wMlAyODhibl2= MoH3V2FPT0WU
EW-13 M4\Ed2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTBwMEGxNkBvVQ>? MlrmV2FPT0WU
NCI-SNU-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTCNoFSUUN3ME2wMlAyPiCwTR?= Mk\aV2FPT0WU
PSN1 NGD2OpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXzTWM2OD1yLkCxOlUhdk1? M3:2WnNCVkeHUh?=
HUTU-80 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoewTWM2OD1yLkCxOlYhdk1? M{[4WHNCVkeHUh?=
EW-16 MnjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTBwMEKzJI5O MUfTRW5ITVJ?
786-0 NVjFVGxST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3RUoNbUUN3ME2wMlAzOyCwTR?= NV\zO2NyW0GQR1XS
ES1 NHHZbXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFP5OYFKSzVyPUCuNFI3QCCwTR?= NGLtbXdUSU6JRWK=
RKO NHTiT4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvwOmRkUUN3ME2wMlAzPzlibl2= MXLTRW5ITVJ?
ESS-1 M3LNN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;CSIxKSzVyPUCuNFI5PiCwTR?= MYfTRW5ITVJ?
SK-UT-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLsdHBlUUN3ME2wMlAzQTdibl2= NH:3XXdUSU6JRWK=
LB2241-RCC NGP6b|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;XNpFKSzVyPUCuNFMyQCCwTR?= M17Re3NCVkeHUh?=
CHL-1 NWPSTZM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorKTWM2OD1yLkCzNlQhdk1? NGLlOItUSU6JRWK=
SW1783 NYnvcldwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofkTWM2OD1yLkCzN|Yhdk1? NWjxWJkyW0GQR1XS
MEL-JUSO M1fZ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TUPWlEPTB;MD6wN|kyKG6P NH\BV2ZUSU6JRWK=
HT-29 MmW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fNPWlEPTB;MD6wOFE{KG6P MY\TRW5ITVJ?
SNG-M M4nWSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTBwMESyOUBvVQ>? NGXqPHhUSU6JRWK=
TE-15 M{DFVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;kS4ZKSzVyPUCuNFQ3PCCwTR?= MVXTRW5ITVJ?
HOS NUXBeplCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3KT|dKSzVyPUCuNFQ5KG6P MkTuV2FPT0WU
BB65-RCC M2nITGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnzZnJKSzVyPUCuNFUyOiCwTR?= Ml73V2FPT0WU
HCE-4 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIr2PJlKSzVyPUCuNFUzQCCwTR?= M2X3NHNCVkeHUh?=
MHH-ES-1 NETYT4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TiWmlEPTB;MD6wOVMyKG6P M4q4bXNCVkeHUh?=
RPMI-7951 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\YfFdKSzVyPUCuNFU1OSCwTR?= NULEeZZvW0GQR1XS
IST-SL2 MljhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlf3TWM2OD1yLkC1PFQhdk1? MnzEV2FPT0WU
CMK M1jJSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwMEW4OkBvVQ>? M{PMSnNCVkeHUh?=
GR-ST MlHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\4fmlEPTB;MD6wOVk2KG6P M2fwT3NCVkeHUh?=
NALM-6 M2SxNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3L6fmlEPTB;MD6wOlIzKG6P M{HhVHNCVkeHUh?=
RPMI-6666 M2Xi[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTWTWM2OD1yLkC2OVIhdk1? M1vaOHNCVkeHUh?=
LC-2-ad MmW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TWXmlEPTB;MD6wOlU{KG6P NYrH[GxkW0GQR1XS
ARH-77 MmfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEKzVXFKSzVyPUCuNFcyOSCwTR?= NYq1bnRyW0GQR1XS
IST-MEL1 M4CwO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXXTWM2OD1yLkC3NlYhdk1? NUPuZ4d4W0GQR1XS
SW1710 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mly1TWM2OD1yLkC3OVEhdk1? NVj4fld1W0GQR1XS
DEL NH\zWJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\sTWM2OD1yLkC4PFchdk1? NXn0VZFOW0GQR1XS
AGS MlTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGf5RVJKSzVyPUCuNFkxOiCwTR?= NVO3fpZnW0GQR1XS
NCI-H2122 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDxZ3JKSzVyPUCuNFk1PiCwTR?= NUToZ2NyW0GQR1XS
HSC-4 NHizdpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTBwMUCyJI5O NIjFSJVUSU6JRWK=
AM-38 NGq3XolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjXTWM2OD1yLkGyNUBvVQ>? NVLWcXluW0GQR1XS
769-P M4K1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfxNoQ1UUN3ME2wMlEzOyCwTR?= M2DZeHNCVkeHUh?=
RT-112 M2qxS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrLZVNJUUN3ME2wMlEzPyCwTR?= NYnLPY5VW0GQR1XS
MCF7 NFjXNHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkC4TWM2OD1yLkGzOkBvVQ>? M4j1S3NCVkeHUh?=
IGROV-1 NUTafnc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTBwMUS1JI5O NXvp[lR[W0GQR1XS
OCI-AML2 M2Hp[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlm2TWM2OD1yLkG0O{BvVQ>? MmqwV2FPT0WU
NCI-H1299 Mo\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTBwMUW3JI5O NH\ub4JUSU6JRWK=
A431 MmXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlv6TWM2OD1yLkG4N{BvVQ>? MXzTRW5ITVJ?
SW982 M{jEc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\QRmlEPTB;MD6yNVMhdk1? NIC2bmZUSU6JRWK=
BB30-HNC MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWiyUYxEUUN3ME2wMlI{OSCwTR?= NYTC[VFPW0GQR1XS
ACN NV7lUmxHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnmUXJbUUN3ME2wMlI1PCCwTR?= MnnpV2FPT0WU
647-V NEjKVZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULNd4ZLUUN3ME2wMlI1QCCwTR?= MUfTRW5ITVJ?
SK-PN-DW M{T4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPiTWM2OD1yLkK2OkBvVQ>? MlPzV2FPT0WU
LCLC-97TM1 M4GxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzvV2NIUUN3ME2wMlI3PyCwTR?= M3jkcnNCVkeHUh?=
LB1047-RCC MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;vUpVKSzVyPUCuNlY6KG6P NWi5TXA1W0GQR1XS
A2780 NX;1ZXc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTBwMkegcm0> MXjTRW5ITVJ?
C-33-A NXjpSXNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2S2TmlEPTB;MD6yO|Mhdk1? NF;iO4dUSU6JRWK=
NCI-H2228 NWnhd|RVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPsTWM2OD1yLkOxOEBvVQ>? NHyySphUSU6JRWK=
TE-5 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TSVWlEPTB;MD6zNVYhdk1? NUDMNldXW0GQR1XS
HC-1 NUHweHJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTBwM{K3JI5O MVfTRW5ITVJ?
SK-MES-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPhTWNKSzVyPUCuN|I5KG6P NIC3V4pUSU6JRWK=
NCI-H1355 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rjXWlEPTB;MD6zPFEhdk1? MUXTRW5ITVJ?
YKG-1 Mom1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jIZ2lEPTB;MD60NVkhdk1? MYPTRW5ITVJ?
RS4-11 NGTkdYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\tTWM2OD1yLkSzN{BvVQ>? Mo\XV2FPT0WU
Daoy Mn;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfCXnBpUUN3ME2wMlQ2PiCwTR?= NVfUfGNwW0GQR1XS
A3-KAW NXjkflVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXMTWM2OD1yLkW1NUBvVQ>? NYjNc2pZW0GQR1XS
SK-MEL-30 M2\FeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXK4dJI4UUN3ME2wMlU2PCCwTR?= M4qzPXNCVkeHUh?=
U031 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrVfHNKSzVyPUCuOVY2KG6P NFvMeGpUSU6JRWK=
SK-LMS-1 NWS3XmpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDySZpKSzVyPUCuOVc5KG6P NFvPbGJUSU6JRWK=
ES6 NW\LSo5ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTBwNUi2JI5O MVfTRW5ITVJ?
EoL-1-cell NYnFVpRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTBwNkG2JI5O NH;YUmxUSU6JRWK=
NCI-H2009 NIXGPJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTBwNkG5JI5O NVLjdIQ4W0GQR1XS
A4-Fuk NEnOUVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XtbGlEPTB;MD62NlYhdk1? MVzTRW5ITVJ?
KYSE-270 NH;Rb2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PTTmlEPTB;MD62N|Qhdk1? NX\URmVIW0GQR1XS
SK-LU-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfTZ4cyUUN3ME2wMlY2PSCwTR?= NVLnR|g1W0GQR1XS
SW872 NH\GTpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;yTWM2OD1yLke2OUBvVQ>? MV7TRW5ITVJ?
ES8 Ml\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXXTWM2OD1yLke4JI5O MkX5V2FPT0WU
G-402 Mo\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHGfZQ2UUN3ME2wMlc5PCCwTR?= NH;LdJFUSU6JRWK=
ATN-1 MmnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPFNWlKSzVyPUCuPFA4KG6P NYLudGNkW0GQR1XS
DoTc2-4510 M4[2U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTBwOUCxJI5O NUTEcVJ2W0GQR1XS
MES-SA MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fP[GlEPTB;MD65NFUhdk1? MXfTRW5ITVJ?
SF268 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTBwOUK3JI5O MlXZV2FPT0WU
SF539 M2W2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDWUGdzUUN3ME2xMlAzKG6P NF7lN4hUSU6JRWK=
NB69 NGPIPYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTFwMEWgcm0> NF35Oo5USU6JRWK=
8505C NXHoc2wzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTFwME[gcm0> MkK5V2FPT0WU
CAL-12T NGTvRYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fhcGlEPTB;MT6wPEBvVQ>? NYPUOWJwW0GQR1XS
BHY NVO1[IVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTFwMUSgcm0> MXHTRW5ITVJ?
LB647-SCLC NEnZZZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moq3TWM2OD1zLkG4JI5O M4PMNnNCVkeHUh?=
CAL-62 NGO2cnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3GTWM2OD1zLkKyJI5O M2nHO3NCVkeHUh?=
MEG-01 NEHYU4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3tVnFKSzVyPUGuNlchdk1? Ml\qV2FPT0WU
MG-63 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHI[4hKSzVyPUGuN|Mhdk1? M3;jOXNCVkeHUh?=
SW620 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTFwM{Wgcm0> NYjpdolsW0GQR1XS
A388 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPpblJKSzVyPUGuN|Yhdk1? MWfTRW5ITVJ?
BCPAP MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3S2OWlEPTB;MT60OUBvVQ>? M3;iXnNCVkeHUh?=
P30-OHK NGLodnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\BZXBjUUN3ME2xMlQ3KG6P M1S1ZXNCVkeHUh?=
Ca9-22 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfFUWJNUUN3ME2xMlU1KG6P Mon5V2FPT0WU
VMRC-RCZ NGH1So5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2n4VGlEPTB;MT61OEBvVQ>? NX;3OGJJW0GQR1XS
LOXIMVI NV3DOZFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{ewUWlEPTB;MT62JI5O MoLxV2FPT0WU
L-540 MoLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7aTWM2OD1zLk[gcm0> M1\WXHNCVkeHUh?=
NTERA-S-cl-D1 M1jvNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fuUmlEPTB;MT62OEBvVQ>? MlvqV2FPT0WU
MFH-ino M2DZN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3JTWM2OD1zLk[2JI5O M{XiUXNCVkeHUh?=
Calu-6 NWfBS5pkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTBe5U6UUN3ME2xMlc{KG6P NILxSHFUSU6JRWK=
HEL Mo[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTFwN{mgcm0> Mom0V2FPT0WU
CAL-33 M2PiUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3NPZJGUUN3ME2xMlg6KG6P MVHTRW5ITVJ?
HSC-3 M3H3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTFwOUGgcm0> NUewXlhZW0GQR1XS
KU812 M2X2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTFwOUGgcm0> M3XrRXNCVkeHUh?=
EB2 NGmw[|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\ITWM2OD1{LkCxJI5O MVPTRW5ITVJ?
SR MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTJwMUKgcm0> MYTTRW5ITVJ?
NCI-H2087 NUHkRnZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnv5TWM2OD1{LkG0JI5O M{LxVnNCVkeHUh?=
H4 NWToboN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPKTWM2OD1{LkG4JI5O M3PZ[nNCVkeHUh?=
EW-1 NVTKbmpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTJwMkKgcm0> M3\lTnNCVkeHUh?=
MC-IXC MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDNTWM2OD1{LkK2JI5O NYWxbFRuW0GQR1XS
NCI-H727 NV2yfIFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTJwNUGgcm0> MoHrV2FPT0WU
MRK-nu-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLjTWM2OD1{LkW3JI5O NYHYT|FtW0GQR1XS
COLO-668 M4K4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3STWM2OD1{Lk[2JI5O NGrpOYZUSU6JRWK=
CGTH-W-1 NXHBOIpuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\vTWM2OD1{LkeyJI5O NXzZVW51W0GQR1XS
CHP-212 M{HzSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjJNGlKSzVyPUKuO|Uhdk1? Mnr2V2FPT0WU
GI-1 M1\vOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTkV2dsUUN3ME2yMlc3KG6P MXjTRW5ITVJ?
HCC1806 NHH1VZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnoW5VDUUN3ME2yMlkyKG6P NFvqSYlUSU6JRWK=
HLE MkKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWmyZodEUUN3ME2zJI5O NVS2eIRIW0GQR1XS
HSC-2 MmfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWn5PGFPUUN3ME2zMlA{KG6P NHL1R|dUSU6JRWK=
DMS-273 NF;lUZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnaTWM2OD1|LkC3JI5O MX7TRW5ITVJ?
DU-4475 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nBPGlEPTB;Mz6xOEBvVQ>? NIrTbmNUSU6JRWK=
LXF-289 M{jyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTSTWM2OD1|LkOxJI5O NVrsemFWW0GQR1XS
PANC-03-27 NHG3[nJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PkSGlEPTB;Mz61NUBvVQ>? MVnTRW5ITVJ?
GAMG MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnv2TWM2OD1|Lke0JI5O MorDV2FPT0WU
NCI-H522 M3;zWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NET3XoNKSzVyPUSuN|Qhdk1? MV7TRW5ITVJ?
SW626 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjiTWM2OD12LkS2JI5O M4LnVnNCVkeHUh?=
HT-144 Mn7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17OZmlEPTB;ND65NkBvVQ>? MX;TRW5ITVJ?
MEL-HO M2C2bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPGS|RKSzVyPUWuNVYhdk1? M2DKWnNCVkeHUh?=
BE-13 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPmWo43UUN3ME21MlIyKG6P M2HqdnNCVkeHUh?=
VA-ES-BJ NVzjdHRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXhTWM2OD13LkK2JI5O MojUV2FPT0WU
NCI-H441 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHPXGxrUUN3ME21MlYhdk1? NIL2UVZUSU6JRWK=
KP-4 M1e4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPnNWZKSzVyPUWuOlEhdk1? NX\iOppbW0GQR1XS
LoVo NY\yOIpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTVwN{Ggcm0> NHvESWpUSU6JRWK=
HT-1080 MlzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HXbWlEPTB;NT64N{BvVQ>? M3\FTXNCVkeHUh?=
GB-1 NUXFR5FZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTVwOESgcm0> MoPQV2FPT0WU
IA-LM M3nYcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7NTWM2OD13LkmxJI5O NW\vflZuW0GQR1XS
8-MG-BA NULQUY1LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TydGlEPTB;NT65N{BvVQ>? MorvV2FPT0WU
SK-HEP-1 MlXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXKxNnhmUUN3ME22MlE1KG6P NGHHdGRUSU6JRWK=
697 Mm\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DxeWlEPTB;Nj6yOUBvVQ>? MV7TRW5ITVJ?
KYSE-450 M{XqOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjLco1PUUN3ME22MlMzKG6P M36yPXNCVkeHUh?=
HCC2998 MoSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETZTGlKSzVyPU[uN|Qhdk1? MlPkV2FPT0WU
HD-MY-Z NHGwbJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DsfGlEPTB;Nj62PEBvVQ>? MnznV2FPT0WU
OS-RC-2 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zubmlEPTB;Nj62PEBvVQ>? MmH2V2FPT0WU
SF126 NEHVS5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnYTWM2OD15LkC1JI5O NYHpT2djW0GQR1XS
Ca-Ski NILm[25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTdwMEmgcm0> NIjab4VUSU6JRWK=
NCI-H358 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTdwMU[gcm0> M2TlfHNCVkeHUh?=
J82 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HQfmlEPTB;Nz60NUBvVQ>? M{CxeHNCVkeHUh?=
NCI-H2342 NIXrWFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTdwNkOgcm0> MlfxV2FPT0WU
OVCAR-8 M{HiS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3OTWM2OD15Lkmgcm0> NXH4XZQ3W0GQR1XS
TE-8 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjvTXpKSzVyPUigcm0> NUH0cI9mW0GQR1XS
ETK-1 MoPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;lToVWUUN3ME24MlA5KG6P NHToO3pUSU6JRWK=
HAL-01 NVPWbGpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljJTWM2OD16LkKgcm0> MlPJV2FPT0WU
KYSE-150 Mn;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\icVhKSzVyPUiuOFchdk1? MXzTRW5ITVJ?
NCI-H810 MknxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HqRmlEPTB;OD61OkBvVQ>? M{WyUHNCVkeHUh?=
ONS-76 Mmn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTyTWM2OD16Lk[4JI5O MVPTRW5ITVJ?
NMC-G1 NX;YdW4xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRThwN{[gcm0> NYDyNHZLW0GQR1XS
C3A NGDVT3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jQ[mlEPTB;OD64OEBvVQ>? NHnVcZVUSU6JRWK=
PA-1 MnjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{n3eGlEPTB;OD65PUBvVQ>? NW\y[pZJW0GQR1XS
SH-4 NH7sPGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPjTWM2OD17LkCyJI5O NHHLdFRUSU6JRWK=
EFO-27 Mof0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jvSGlEPTB;OT6wOUBvVQ>? MkHJV2FPT0WU
CAPAN-1 MnrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF23VlJKSzVyPUmuNlMhdk1? M4H5cnNCVkeHUh?=
DU-145 NWXFOpg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTlwMkmgcm0> NIfPSYZUSU6JRWK=
A101D M4LUWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjsOFN7UUN3ME25MlM4KG6P M2KxTnNCVkeHUh?=
ST486 NGfjNXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPrTWM2OD17LkSxJI5O MnT6V2FPT0WU
NCI-H1437 M4TvXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknrTWM2OD17LkSyJI5O MmHvV2FPT0WU
HGC-27 NUj4RXJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTlwNjDuUS=> NVThcnNIW0GQR1XS
8305C NFToe5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHhXG1kUUN3ME25MlY1KG6P NFvn[XVUSU6JRWK=
OCUB-M MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;TR2lEPTB;MUCuNFMhdk1? NG\qVnBUSU6JRWK=
COLO-679 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7EWIU3UUN3ME2xNE4xPyCwTR?= NIrJWWdUSU6JRWK=
Detroit562 MkTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnJXoJNUUN3ME2xNE41OiCwTR?= NYrP[3BwW0GQR1XS
A204 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fvVGlEPTB;MUGuNVYhdk1? NUjXU2c2W0GQR1XS
NCI-H1734 MkHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXKze4g{UUN3ME2xNU4zQSCwTR?= NEHMRmtUSU6JRWK=
MC-CAR MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HxN2lEPTB;MUGuOVghdk1? NGLOTFVUSU6JRWK=
NCI-H2170 Mof5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTFzLkm3JI5O MkTqV2FPT0WU
NCI-SNU-5 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULEOlV2UUN3ME2xNk4yOyCwTR?= NGXxUolUSU6JRWK=
HCE-T MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTF{LkSyJI5O NX:3RlNuW0GQR1XS
KYSE-180 MkXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\vVGlEPTB;MUKuPFEhdk1? Mk[xV2FPT0WU
C8166 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInpNXFKSzVyPUGzMlA5KG6P NEHSW4VUSU6JRWK=
NCI-H460 M1rKUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\SNnpwUUN3ME2xN{42PCCwTR?= NYjxeVFIW0GQR1XS
SNU-449 Mm[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XkemlEPTB;MUOuO|chdk1? M{DqTXNCVkeHUh?=
MDA-MB-468 NFW2OVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\mcFVIUUN3ME2xOE4yOiCwTR?= NGi2cG1USU6JRWK=
COR-L23 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTLdZpKSzVyPUG0MlE{KG6P NVPwUWFGW0GQR1XS
CTV-1 NHywUWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTF2LkG0JI5O MlPSV2FPT0WU
BL-41 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml61TWM2OD1zND6zO{BvVQ>? MlHWV2FPT0WU
IGR-1 NYPMcIZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DxfWlEPTB;MUSuOFIhdk1? MlLyV2FPT0WU
TK10 NGXIZ4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIe2SppKSzVyPUG0MlQ6KG6P Mk\SV2FPT0WU
REH M1u4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\6OYVKSzVyPUG0MlUyKG6P MYjTRW5ITVJ?
LU-139 M1Habmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PadGlEPTB;MUSuOVkhdk1? NEHiXpBUSU6JRWK=
KP-N-YS MmXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnOUJVRUUN3ME2xOE46PyCwTR?= NVvo[49zW0GQR1XS
PANC-10-05 MmD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XYbGlEPTB;MUWuN|ghdk1? NH;FWGhUSU6JRWK=
HL-60 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnGOG9KSzVyPUG1MlY6KG6P M3y2enNCVkeHUh?=
T84 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn36TWM2OD1zNT65OkBvVQ>? NYW2elI2W0GQR1XS
RPMI-8226 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTF4LkCyJI5O MkHMV2FPT0WU
UM-UC-3 MkXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfoVoNPUUN3ME2xOk4yPiCwTR?= NXnuTZNyW0GQR1XS
TE-10 NWrtc4ZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTF4LkKxJI5O NH7mUoxUSU6JRWK=
CAL-148 M1j5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mon4TWM2OD1zNz6yN{BvVQ>? NGj3RmVUSU6JRWK=
BV-173 MnnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTKb|dKSzVyPUG3MlI4KG6P MYrTRW5ITVJ?
Calu-3 NWL5cIZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTF5LkK5JI5O NH;xcGJUSU6JRWK=
RPMI-2650 NIfIXHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3r6VGlEPTB;MUeuOVkhdk1? NFPmSlZUSU6JRWK=
MKN45 NGnYe2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXrS5RKSzVyPUG3Mlc{KG6P NXT0Wpg{W0GQR1XS
NUGC-3 MljkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV2yfYZmUUN3ME2xPE4{PCCwTR?= MXvTRW5ITVJ?
NCI-H520 MnW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTF6Lke3JI5O Ml75V2FPT0WU
CCRF-CEM NGjCZWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEO1WXJKSzVyPUG4Mlg2KG6P MlvUV2FPT0WU
NCI-H2405 NXTkSVB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFroVYFKSzVyPUG5MlEhdk1? MoT5V2FPT0WU
ES7 M{DLOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVizXpJ5UUN3ME2xPU44PiCwTR?= M{e5[3NCVkeHUh?=
BPH-1 MlPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfSTWM2OD1{MD6yPEBvVQ>? MUTTRW5ITVJ?
SAS NILySHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jZeGlEPTB;MkCuOUBvVQ>? M4\VVXNCVkeHUh?=
HuCCT1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlX1TWM2OD1{MD61PEBvVQ>? MU\TRW5ITVJ?
LOUCY M1TBSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTJyLk[2JI5O M2TMR3NCVkeHUh?=
NCI-H292 NWe0ZlFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzqTWM2OD1{MD63PUBvVQ>? NXrqcGRqW0GQR1XS
G-361 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnRO3BKSzVyPUKxMlA4KG6P M2r0O3NCVkeHUh?=
M059J M2TzXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\zemlEPTB;MkGuNFghdk1? NWP5dnZQW0GQR1XS
NCI-H1651 NGrRfXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTKTWM2OD1{MT6xNUBvVQ>? NIPEfpBUSU6JRWK=
KALS-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zqWWlEPTB;MkGuN|khdk1? NF7menRUSU6JRWK=
DJM-1 Ml;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2P5cmlEPTB;MkGuOVkhdk1? NVOzcYMyW0GQR1XS
AU565 NHHzd4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PqbmlEPTB;MkGuPFMhdk1? M1jiV3NCVkeHUh?=
HCC38 M3XMO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnGVGRmUUN3ME2yNU46PSCwTR?= Mn;DV2FPT0WU
U251 NX7TUIltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TicmlEPTB;MkKuNlchdk1? MmTrV2FPT0WU
ABC-1 NYHKOZZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTJ{Lk[1JI5O MXHTRW5ITVJ?
SK-NEP-1 Mn:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPBbZZkUUN3ME2yNk46OyCwTR?= MYTTRW5ITVJ?
CESS MnXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MluxTWM2OD1{Mz6xPUBvVQ>? Mlv1V2FPT0WU
MIA-PaCa-2 NHjTe4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELKUVhKSzVyPUKzMlM3KG6P M3\XenNCVkeHUh?=
SUP-T1 NF30VGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTJ|LkS3JI5O M{HsZ3NCVkeHUh?=
L-428 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDrTWM2OD1{Mz62NkBvVQ>? NHzMdGtUSU6JRWK=
SW954 MmXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTJ|Lk[4JI5O M4nDOXNCVkeHUh?=
HO-1-N-1 MnSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWf3RoFjUUN3ME2yN{44PyCwTR?= MVLTRW5ITVJ?
CHP-126 NUTKXlZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVWyTIZZUUN3ME2yOE4yPCCwTR?= MUTTRW5ITVJ?
HMV-II M1LuNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HiS2lEPTB;MkSuN|Qhdk1? MnrDV2FPT0WU
NB10 NWqzT2RpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmOxTWM2OD1{ND6zO{BvVQ>? Mke5V2FPT0WU
A172 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHZTWM2OD1{ND63NUBvVQ>? M3yzU3NCVkeHUh?=
MONO-MAC-6 MlPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{ftVWlEPTB;MkSuPFQhdk1? M1X4cHNCVkeHUh?=
NCI-H1650 MmLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPn[IJKSzVyPUK1MlQhdk1? NGrQUoRUSU6JRWK=
NH-12 NH\UcpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLVfo1KSzVyPUK1MlUhdk1? NFzkZ5dUSU6JRWK=
ML-2 MofDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoX1TWM2OD1{NT63OEBvVQ>? MkDxV2FPT0WU
MZ2-MEL NYLYR2QzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTJ4LkKyJI5O NHXiXGJUSU6JRWK=
COLO-684 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUK3SZF[UUN3ME2yOk41OSCwTR?= MU\TRW5ITVJ?
HuP-T4 NW\WO5loT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;X[4xQUUN3ME2yO{4{KG6P M1\EenNCVkeHUh?=
SW837 M4mye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDQcGJKSzVyPUK3MlYzKG6P MnrmV2FPT0WU
MDA-MB-231 NHLSbXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzBbo5KSzVyPUK3Mlc5KG6P MV\TRW5ITVJ?
KYSE-140 M{HOUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXBTWM2OD1{Nz65NUBvVQ>? NHLRcW9USU6JRWK=
NOMO-1 NXuyPVVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\jZWpKSzVyPUK4MlY5KG6P NX[2[Ws1W0GQR1XS
GP5d NGrWbWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HyPWlEPTB;MkiuO|Ihdk1? M3rvRXNCVkeHUh?=
COR-L105 NXzQR|hXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzoUlFZUUN3ME2yPU41OiCwTR?= MXfTRW5ITVJ?
LS-411N MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTJ7Lki4JI5O NVy3XWVqW0GQR1XS
NY MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\jbmlEPTB;M{CuNVghdk1? MXHTRW5ITVJ?
NCI-H2030 NVXOeFBGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjFNmhKSzVyPUOwMlQ2KG6P MmXoV2FPT0WU
CCF-STTG1 M2H0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTNzLkSyJI5O M3LaUHNCVkeHUh?=
NCI-H1703 NGDoR|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nsemlEPTB;M{GuO|ghdk1? NFO1XZZUSU6JRWK=
TUR M37jSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3m3emlEPTB;M{KuNFMhdk1? NX3JeGhYW0GQR1XS
NOS-1 NUDpZmk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;aTWM2OD1|Mj60OEBvVQ>? MlHmV2FPT0WU
A2058 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGf3[mlKSzVyPUOyMlg{KG6P MlHGV2FPT0WU
LCLC-103H MnXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTN|LkK1JI5O NWrPVlQ2W0GQR1XS
NCI-H510A MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPZdYxLUUN3ME2zN{4zPyCwTR?= NH;rTnNUSU6JRWK=
BC-1 NUXVfnU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPSN5hKSzVyPUOzMlc4KG6P NVi0[3N3W0GQR1XS
SK-CO-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DBbGlEPTB;M{SuNFEhdk1? M2nJNXNCVkeHUh?=
A673 M13uUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvCTWM2OD1|ND6xO{BvVQ>? M3fOWHNCVkeHUh?=
VM-CUB-1 NXjFR3JiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUf1OopOUUN3ME2zOE43QSCwTR?= M1jBXXNCVkeHUh?=
HH MmPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLLTWM2OD1|NT6wOkBvVQ>? MXPTRW5ITVJ?
CAL-27 MmrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTN3LkG2JI5O NXji[HpDW0GQR1XS
NEC8 M2[wOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7CTWM2OD1|NT6zO{BvVQ>? MmjGV2FPT0WU
BxPC-3 M2\DZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjsc2x3UUN3ME2zOk46OSCwTR?= MoXCV2FPT0WU
SNB75 MnixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrnTWM2OD1|Nz6yOEBvVQ>? NV;pZYYzW0GQR1XS
NB13 MoXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInNW4dKSzVyPUO4MlI{KG6P MlHxV2FPT0WU
SK-OV-3 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\FZmlEPTB;M{iuO|Qhdk1? NIT4WlZUSU6JRWK=
ME-180 NGLGSGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrjcIduUUN3ME2zPE45KG6P NWTlR|NpW0GQR1XS
JiyoyeP-2003 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTN7LkO4JI5O M2HaPHNCVkeHUh?=
LU-134-A MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7vTmlKSzVyPUSwMlAzKG6P MWfTRW5ITVJ?
LS-123 M1nnW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH:2VnlKSzVyPUSwMlI5KG6P NV[zeYN[W0GQR1XS
COLO-800 M1fSNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInFXYJKSzVyPUSwMlU3KG6P M3nIeXNCVkeHUh?=
LB831-BLC M2q1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\ZdWlEPTB;NEGuPFUhdk1? MnK1V2FPT0WU
NCI-H747 NYXTVY9xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorjTWM2OD12Mj6yPEBvVQ>? NVHRRWV5W0GQR1XS
MZ7-mel M{[yRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHraXZhKSzVyPUSyMlY3KG6P MnHrV2FPT0WU
GT3TKB MkDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\HeJE3UUN3ME20Nk44OiCwTR?= NFnkUFdUSU6JRWK=
MOLT-16 M3zxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfrTWM2OD12Mz6wOUBvVQ>? MkHnV2FPT0WU
23132-87 MoDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojTTWM2OD12Mz6wOUBvVQ>? MnfsV2FPT0WU
PF-382 NXizPJBGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTR2LkKyJI5O MXHTRW5ITVJ?
ES3 MnPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTR2Lk[gcm0> MoHhV2FPT0WU
SW756 MnXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mny2TWM2OD12NT6xOEBvVQ>? M2PJe3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Gemcitabine combined with C225 results in growth inhibition, tumor regression, and abrogation of metastasis in L3.6pl tumors established in the pancreas of nude mice. Gemcitabine treatment alone reduces median tumor volume from 538 to 152 mm3. Gemcitabine reduces the production of vascular endothelial growth factor and interleukin 8 in gemcitabine-treated tumors. [2] Gemcitabine is able to dramatically and specifically reduces the number of myeloid suppressor cells found in the spleens of animals bearing large tumors with no significant reductions in CD4(+) T cells, CD8(+) T cells, NK cells, macrophages, or B cells. [4] Gemcitabine combined with curcumin shows significant reductions in volume (P = 0.008 versus control; P = 0.036 versus gemcitabine alone), Ki-67 proliferation index (P = 0.030 versus control), NF-kappaB activation, and expression of NF-kappaB-regulated gene products (cyclin D1, c-myc, Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein-1, cyclooxygenase-2, matrix metalloproteinase, and vascular endothelial growth factor) compared with tumors from control mice treated with olive oil only. Gemcitabine combined with Curcumin is also highly effective in suppressing angiogenesis as indicated by a decrease in CD31(+) microvessel density. [5]

Protocol

Solubility (25°C)

In vitro Water 16 mg/mL (60.79 mM) warming
DMSO 15 mg/mL (56.99 mM)
Ethanol <1 mg/mL
In vivo water warming 16mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 263.2
Formula

C9H11F2N3O4

CAS No. 95058-81-4
Storage powder
in solvent
Synonyms LY-188011, NSC 613327

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02181634 Active, not recruiting Cholangiocarcinoma PrECOG, LLC.|Celgene Corporation December 9, 2014 Phase 2
NCT01535924 Recruiting Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Lymphocyte Predominant Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Recurrent Adult Hodgkin Lymphoma Kristie Blum|Ohio State University Comprehensive Cancer Center February 9, 2012 Phase 1|Phase 2
NCT01285037 Recruiting Cancer Eli Lilly and Company September 9, 2009 Phase 1
NCT01828736 Completed Recurrent Bladder Cancer|Stage IV Bladder Cancer|Transitional Cell Carcinoma of the Bladder Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie|Roche Pharma AG February 9, 2004 Phase 2
NCT01352962 Active, not recruiting Urethral Neoplasms|Neoplasms, Urethral|Ureter Cancer|Cancer of the Urethra|Urethral Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 5, 2011 Phase 1
NCT03027284 Recruiting Advanced Cancer|Metastatic Cancer|Biliary Tract Carcinoma|Cholangiocarcinoma|Gall Bladder Carcinoma|Solid Tumor|Non-Hodgkins Lymphoma Eli Lilly and Company February 3, 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Gemcitabine | Gemcitabine ic50 | Gemcitabine price | Gemcitabine cost | Gemcitabine solubility dmso | Gemcitabine purchase | Gemcitabine manufacturer | Gemcitabine research buy | Gemcitabine order | Gemcitabine mouse | Gemcitabine chemical structure | Gemcitabine mw | Gemcitabine molecular weight | Gemcitabine datasheet | Gemcitabine supplier | Gemcitabine in vitro | Gemcitabine cell line | Gemcitabine concentration | Gemcitabine nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID